ES2189079T3 - Efectos inmunosupresores de derivados de xantina 8-sustituidos. - Google Patents
Efectos inmunosupresores de derivados de xantina 8-sustituidos.Info
- Publication number
- ES2189079T3 ES2189079T3 ES98201323T ES98201323T ES2189079T3 ES 2189079 T3 ES2189079 T3 ES 2189079T3 ES 98201323 T ES98201323 T ES 98201323T ES 98201323 T ES98201323 T ES 98201323T ES 2189079 T3 ES2189079 T3 ES 2189079T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- carbon atoms
- unsubstituted
- phenyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA INVENCION SE REFIERE A UN NUEVO USO DE DERIVADOS DE LA XANTINA 8-SUSTITUIDA PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES. LA INVENCION SE REFIERE EN PARTICULAR A LA UTILIZACION DE UN DERIVADO DE LA XANTINA DE LA FORMULA GENERAL (I) EN DONDE: R 1 , R 2 Y R 3 SON INDEPENDIENTEMENTE HIDROGENO, CADENAS ALIFATICAS SATURADAS O INSATURADAS QUE PUEDEN SER RECTAS O RAMIFICADAS QUE TIENEN ENTRE 1 Y 6 ATOMOS DE CARBONO; X E Y SON INDEPENDIENTEMENTE OXIGENO O AZUFRE; Z 1 SE SELECCIONA ENTRE EL GRUPO QUE CONSTA DE TIENILO; FURANILO; CICLOPENTILO, FENILO O UN FENILO SUSTITUIDO POR 2 O INSUSTITUIDO; EN DONDE Z 2 SE SELECCIONA ENTRE EL GRUPO QUE CONSTA DE FENILO; ACIDO SULFONICO; SULFONAMIDA INSUSTITUIDA O N-SUSTITUIDA CON SUSTITUYENTES TALES COMO ALQUILO, AMINOALQUILO EN DONDE EL GRUPO DE AMINO PUEDE ESTAR EL MISMO SUSTITUIDO CON GRUPOS DE ALQUILO INFERIOR QUE SOPORTAN ENTRE 1 Y 4 ATOMOS DE CARBONO; NITRO; UN GRUPO DE AMINO SUSTITUIDO CON HALOGENO O INSUSTITUIDO; UNA CADENA ALIFATICA CON ENTRE 1 Y 3 ATOMOS DE CARBONO; UNA CADENA ALIFATICA HOLOGENADA CON ENTRE 1 Y 3 ATOMOS DE CARBONO; UNA CADENA ALIFATICA QUE CONTIENE FUNCIONES DE ETER, ACIDOS, ESTERES, AMIDOS, AMINOS SUSTITUIDOS O INSUSTITUIDOS QUE TIENEN ENTRE 1 Y 3 ATOMOS DE CARBONO, NITRO, SULFONAMIDOS O UNA COMBINACION DE ESTOS GRUPOS FUNCIONALES CON UN LONGITUD MAXIMA DE LA CADENA DE 12 ATOMOS. TAMBIEN SE PRESENTAN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS DERIVADOS QUE SE UTILIZAN PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98201323A EP0956855B1 (en) | 1998-04-24 | 1998-04-24 | Immunosuppressive effects of 8 substituted xanthine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2189079T3 true ES2189079T3 (es) | 2003-07-01 |
Family
ID=8233642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98201323T Expired - Lifetime ES2189079T3 (es) | 1998-04-24 | 1998-04-24 | Efectos inmunosupresores de derivados de xantina 8-sustituidos. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0956855B1 (es) |
| AT (1) | ATE234099T1 (es) |
| DE (1) | DE69812070T2 (es) |
| DK (1) | DK0956855T3 (es) |
| ES (1) | ES2189079T3 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU770551B2 (en) * | 1998-12-28 | 2004-02-26 | 4-Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| AU2002359365B2 (en) | 2001-11-09 | 2008-07-10 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| MXPA03008967A (es) * | 2002-02-01 | 2004-02-12 | King Pharmaceuticals Res & Dev | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| EP1599477B1 (en) * | 2003-02-19 | 2008-01-30 | F. Hoffmann-La Roche Ag | Sulfonamide substituted xanthine derivatives for use as pepck inhibitors |
| WO2004106337A1 (en) * | 2003-05-06 | 2004-12-09 | Cv Therapeutics, Inc. | Xanthine derivatives as a2b adenosine receptor antagonists |
| AU2011202523B2 (en) * | 2003-11-21 | 2013-05-30 | Gilead Sciences, Inc. | A2B adenosine receptor antagonists |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008009079A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| WO2008140895A1 (en) | 2007-04-20 | 2008-11-20 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| CA2742007C (en) | 2008-10-29 | 2014-07-08 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| NZ731344A (en) | 2014-10-09 | 2018-08-31 | Guangdong Raynovent Biotech Co Ltd | Hydroxyl purine compounds and applications thereof |
| CN111233863B (zh) * | 2014-10-09 | 2022-10-25 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| SG11201606876RA (en) | 2015-03-04 | 2016-10-28 | Gilead Sciences Inc | Toll like receptor modulator compounds |
| SI3507276T1 (sl) | 2016-09-02 | 2022-01-31 | Gilead Sciences, Inc. | Spojine modulatorja toličnih receptorjev |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| CN110041330B (zh) * | 2018-01-16 | 2020-08-11 | 新发药业有限公司 | 一种伊曲茶碱的环保制备方法 |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| IL330104A (en) | 2019-03-11 | 2026-08-01 | Deciphera Pharmaceuticals Llc | Crystalline forms of rifatinib |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| HRP20260411T1 (hr) | 2019-08-12 | 2026-05-08 | Deciphera Pharmaceuticals, Llc | Ripretinib za liječenje gastrointestinalnih stromalnih tumora |
| US12691108B2 (en) | 2019-08-12 | 2026-07-28 | Deciphera Pharmaceuticals, Llc | Methods for treating vascular malformations |
| CN110922363A (zh) * | 2019-12-28 | 2020-03-27 | 新华制药(寿光)有限公司 | 一种紫脲酸连续化生产工艺 |
| FI4084779T3 (fi) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL100195A0 (en) * | 1990-11-30 | 1992-08-18 | Hoechst Roussel Pharma | Use of xanthines for the preparation of a medicament having immuno suppressing activity |
| WO1996036638A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | Xanthines and their therapeutic use |
-
1998
- 1998-04-24 DE DE69812070T patent/DE69812070T2/de not_active Expired - Fee Related
- 1998-04-24 EP EP98201323A patent/EP0956855B1/en not_active Expired - Lifetime
- 1998-04-24 DK DK98201323T patent/DK0956855T3/da active
- 1998-04-24 ES ES98201323T patent/ES2189079T3/es not_active Expired - Lifetime
- 1998-04-24 AT AT98201323T patent/ATE234099T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0956855A1 (en) | 1999-11-17 |
| DE69812070D1 (de) | 2003-04-17 |
| DE69812070T2 (de) | 2003-12-11 |
| ATE234099T1 (de) | 2003-03-15 |
| EP0956855B1 (en) | 2003-03-12 |
| DK0956855T3 (da) | 2003-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0956855T3 (da) | Immunhæmmende effekter af 8-substituerede xanthin-derivater | |
| EP1035123A4 (en) | NEW HETEROCYCLIC CONNECTIONS | |
| NO933452D0 (no) | Et terapeutisk middel for parkinson's sykdom | |
| ES2065895T3 (es) | 2-aminobenzotiazoles sustituidos y derivados de los mismos utiles como agentes cerebrovasculares. | |
| ATE282614T1 (de) | Phenylharnstoff und phenylthioharnstoffderivate | |
| ES2167676T3 (es) | Resinas epoxi ignifugas y agentes ignifugantes para resinas epoxi. | |
| ATE52498T1 (de) | Amidderivate. | |
| ATE121939T1 (de) | Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion. | |
| HUT46313A (en) | Process for producing 3/2h/-pyridazine derivatives and pharmaceutical compositions containing them as active components | |
| PT941082E (pt) | Nova utilizacao para derivados de 1,3-propanodiol | |
| DK0790987T3 (da) | Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer | |
| BR1100636A (pt) | Agente terapêutico para o mal de parkinson, e, derivado da xantina | |
| FR2598709B1 (fr) | Derives de l'acide quinoleinecarboxylique | |
| ES2110977T3 (es) | Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa. | |
| DK384485D0 (da) | 1,6-naphthyridinderivater med kardilaterende virkning | |
| ES2131549T3 (es) | Derivados macrolidas de 16 eslabones y su procedimiento de preparacion. | |
| ES2061785T3 (es) | Benzopiranos 2,2-disustituidos de utilidad como antagonistas de leucotrieno-d4. | |
| EP0726269A4 (en) | QUINOLINE CARBONIC ACID DERIVATIVE AND ITS SALTS | |
| NO150436C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-derivater | |
| KR910000150A (ko) | 대사성 골 질환 치료제 | |
| EP0802179A4 (en) | DERIVATE SUBSTITUTED AMIDINONAPHTHYLESTER | |
| DE69532963D1 (de) | Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen |